| Name | Value |
|---|---|
| Revenues | 554.9K |
| Cost of Revenue | 190.8K |
| Gross Profit | 364.1K |
| Operating Expense | 5,482.5K |
| Operating I/L | -5,118.4K |
| Other Income/Expense | -289.3K |
| Interest Income | 124.0K |
| Pretax | -5,407.7K |
| Income Tax Expense | 1.2K |
| Net Income/Loss | -5,408.9K |
Femasys Inc. is a biomedical company specializing in women's healthcare solutions. The company's primary focus is on developing and commercializing a range of products for permanent birth control, artificial insemination, endocervical curettage, and uterine cancer detection testing. Their products, including FemBloc, FemChec, FemaSeed, FemCerv, and FemEMB, are targeted at obstetrics-gynecological physicians, reproductive endocrinologists, and women's healthcare provider organizations. Femasys also offers non-surgical product technologies to support their core offerings, generating revenue from sales in the United States, Europe, Canada, Japan, and other international markets.